La osteoporosis "senile" fue reconsiderada
Video Experimental Relacionado
Updated: Sep 29, 2026
07:12
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
1Joint Department of Medicine, Beth Israel Hospital, Boston, MA.
JAMA
|February 17, 1989
Resumen
La osteoporosis afecta desproporcionadamente a las mujeres mayores, sin embargo, los tratamientos actuales se centran en las personas más jóvenes. Se necesita urgentemente investigación para desarrollar terapias efectivas de osteoporosis para mujeres mayores de 70 años.
Área de la Ciencia:
- Gerontología Gerontología.
- Metabolismo óseo Metabolismo óseo.
- Medicina Geriátrica La medicina geriátrica es una especialidad de la medicina geriátrica.
Sus antecedentes:
- La osteoporosis es un problema de salud importante, que afecta particularmente a las mujeres mayores de 70 años.
- La investigación actual y los tratamientos para la osteoporosis se dirigen principalmente a las mujeres perimenopáusicas.
- Hay diferencias críticas en la salud ósea entre las mujeres perimenopáusicas y posmenopáusicas mayores de 70 años.
Objetivo del estudio:
- Para resaltar la insuficiencia de los tratamientos actuales de la osteoporosis para las mujeres mayores.
- Para enfatizar la necesidad de investigación adaptada al metabolismo óseo específico y los riesgos de fractura en mujeres mayores de 70.
- Sugerir futuras direcciones de investigación para la prevención y el tratamiento de la osteoporosis en la población anciana.
Principales métodos:
- Revisión de la literatura existente sobre la osteoporosis en mujeres perimenopáusicas versus mujeres mayores.
- Análisis de las diferencias en el metabolismo mineral óseo, las tasas de pérdida ósea y la integridad estructural ósea.
- Examen de los distintos factores de riesgo y tipos de fracturas prevalentes en las mujeres mayores.
Principales resultados:
- Las terapias actuales de osteoporosis son menos efectivas en mujeres mayores debido a la pérdida ósea más lenta o cesada y la calidad ósea comprometida.
- Los tratamientos existentes pueden no abordar adecuadamente los cambios fisiológicos únicos en el hueso en mujeres mayores de 70 años.
- La efectividad de las modalidades actuales para mitigar las consecuencias de la osteoporosis en este grupo demográfico es limitada.
Conclusiones:
- Las estrategias actuales de manejo de la osteoporosis requieren una reevaluación para las mujeres mayores de 70 años.
- La investigación adicional es fundamental para desarrollar intervenciones específicas y efectivas para la osteoporosis en mujeres mayores.
- Los estudios futuros deben centrarse en las necesidades específicas y los perfiles de riesgo de las mujeres mayores para mejorar la prevención de fracturas y los resultados del tratamiento.
Videos de Conceptos Relacionados
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...